{"id":519827,"date":"2021-07-29T08:04:05","date_gmt":"2021-07-29T12:04:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/"},"modified":"2021-07-29T08:04:05","modified_gmt":"2021-07-29T12:04:05","slug":"impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/","title":{"rendered":"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SEATTLE, July  29, 2021  (GLOBE NEWSWIRE) &#8212; Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that it will host a virtual key opinion leader (KOL) event to review the post triptan failure landscape and new options for the treatment of acute migraine. In addition, the program will cover the role of non-oral acute migraine therapies, including the history of use of dihydroergotamine (DHE), the STOP301 trial results for Impel\u2019s lead product candidate TRUDHESA\u2122 and commercial insights and opportunities in the acute migraine market. The event will take place on Friday, August 6, 2021 at 1:00pm ET.<\/p>\n<p>The event will feature presentations from guest speakers Dr. Wade Cooper, Director of Headache and Neuropathic Pain at the University of Michigan School of Medicine, Dr. Stewart Tepper, Director of Dartmouth Headache Center at the Geisel School of Medicine, Dr. Nada Hindiyeh, Assistant Professor of neurology and neurological systems at Stanford Medical School and Impel NeuroPharma management.<\/p>\n<p>A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HOeur5qF74vTd_9R8yvswIMLMkUiJuXFLcJqmZXylP79GQZCOzrC2a6UbWdnclBgrjsvMfJBkJYzwPuPxf5h1488ne1lMH2TkLyF0GtgqmzN82O0GO6vxJgGKvCaQEFT9IQHZ2Tr0RluCAHbbRNZluGr6UXwauT9Izectbnkwsc4-p-_VOsdokPDfoJ3DdM3A4ypbnkQ0a8Fj2og_W-RXrCprHG5jxqy2sYY48Xxz7AvuzednRAtYtkgN1aif20DKH8l6IhqbRQgLduSt6VGX4jp0noHQZbpkTG4yBpgP3oHBpVO2qCmg6JqhK8JWMDMC3jmgzB5XOvgwLCMUcTxjeyN4pRWB-38yZ0uw6jEfCv69SQwwr4O1bmVoGATFxkTfh2CHECqj9pJWfesM1EgoJyhymC9FfGHrQpAEuVX9HjFzlHRQHVUwKEU2tb_sYDvsmnVqzkPbAGhxvVU1D6HeyI0958goWQ8Q7Uhm-DzLyQ5eyqVVC8NePdbs4hoDPOhnofcyLVtQLMTgnE81mu3GlUURe9f7wCiVlYyM8ui2OFj4hlMcB5Bek-aaAhldlPFrwc72DttsmbaGCsZv8xaABrXo6ZufXJxWCkad9DLQVM=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.impelnp.com\/<\/a>. A replay of the webcast and accompanying slides will be available on the Impel NeuroPharma website following the event.<\/p>\n<p align=\"justify\">\n        <strong>About Impel NeuroPharma<\/strong>\n      <\/p>\n<p align=\"justify\">Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company\u2019s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD\u00ae) system with well-established therapeutics, including TRUDHESA\u2122 for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson\u2019s disease.<\/p>\n<p>\n        <strong>Investor Relations<\/strong>:<br \/>Christina Tartaglia<br \/>Stern Investor Relations<br \/>Phone: (1) 212-362-1200<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Du6T84HJA8OvtMbN4jP-SJ6izLgFLoDxXhiN59Eu1hJNsJhVReIGuHT9WGLob4mjv2KXEtNfTeDEQ-9kqRX8qV_oB8sDs_TRIEcB9Hf8yBgU81noOJrEB8MVjQYq61lh\" rel=\"nofollow noopener\" target=\"_blank\">christina.tartaglia@sternir.com<\/a><\/p>\n<p>\n        <strong>Media Relations<\/strong>:<br \/>Melyssa Weible<br \/>Elixir Health Public Relations<br \/>Phone: (1) 201-723-5805<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HNtEkCwAE5jF0I7DrEgFQatwwaE3mVwdbqrB6dkxXQrerxoMp6Xzxjyu1MbRjJzg2n_X0wnbWQ8mno4KWKbGmsJszbDTBwHap9Igu_Fa4n2SYDC58_LnXGBvV3HlrDuC\" rel=\"nofollow noopener\" target=\"_blank\">mweible@elixirhealthpr.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/46319cc1-01af-437c-92fc-377513a92797\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) &#8212; Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that it will host a virtual key opinion leader (KOL) event to review the post triptan failure landscape and new options for the treatment of acute migraine. In addition, the program will cover the role of non-oral acute migraine therapies, including the history of use of dihydroergotamine (DHE), the STOP301 trial results for Impel\u2019s lead product candidate TRUDHESA\u2122 and commercial insights and opportunities in the acute migraine market. The event will take place on Friday, August 6, 2021 at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-519827","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) &#8212; Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that it will host a virtual key opinion leader (KOL) event to review the post triptan failure landscape and new options for the treatment of acute migraine. In addition, the program will cover the role of non-oral acute migraine therapies, including the history of use of dihydroergotamine (DHE), the STOP301 trial results for Impel\u2019s lead product candidate TRUDHESA\u2122 and commercial insights and opportunities in the acute migraine market. The event will take place on Friday, August 6, 2021 at &hellip; Continue reading &quot;Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T12:04:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021\",\"datePublished\":\"2021-07-29T12:04:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/\"},\"wordCount\":350,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/\",\"name\":\"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI=\",\"datePublished\":\"2021-07-29T12:04:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/","og_locale":"en_US","og_type":"article","og_title":"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021 - Market Newsdesk","og_description":"SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) &#8212; Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that it will host a virtual key opinion leader (KOL) event to review the post triptan failure landscape and new options for the treatment of acute migraine. In addition, the program will cover the role of non-oral acute migraine therapies, including the history of use of dihydroergotamine (DHE), the STOP301 trial results for Impel\u2019s lead product candidate TRUDHESA\u2122 and commercial insights and opportunities in the acute migraine market. The event will take place on Friday, August 6, 2021 at &hellip; Continue reading \"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T12:04:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021","datePublished":"2021-07-29T12:04:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/"},"wordCount":350,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/","name":"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI=","datePublished":"2021-07-29T12:04:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODc4NSM0MzIwNDY4IzIxODczOTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/impel-neuropharma-to-host-virtual-key-opinion-leader-event-on-august-6-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=519827"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519827\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=519827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=519827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=519827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}